Sol-Gel Technologies Ltd. (SLGL) Income Statement Analysis

See more : Golden Energy Offshore Services AS (GEOS.OL) Income Statement Analysis – Financial Results

Complete financial analysis of Sol-Gel Technologies Ltd. (SLGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sol-Gel Technologies Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Société Foncière Lyonnaise (FLY.PA) Income Statement Analysis – Financial Results
Kuehne + Nagel International AG (KNIN.SW) Income Statement Analysis – Financial Results
The Star Entertainment Group Limited (EHGRF) Income Statement Analysis – Financial Results
Lightstone Value Plus Real Estate Investment Trust III, Inc. (LVVR) Income Statement Analysis – Financial Results
Templeton Dragon Fund, Inc. (TDF) Income Statement Analysis – Financial Results

Sol-Gel Technologies Ltd. (SLGL)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.sol-gel.com

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	1.55M	3.88M	31.27M	8.77M	22.90M	129.00K	174.00K	0.00	0.00	0.00
Cost of Revenue	23.54M	12.68M	20.38M	27.91M	40.58M	28.15M	300.00K	359.00K	300.00K	0.00
Gross Profit	-21.99M	-8.80M	10.89M	-19.14M	-17.67M	-28.02M	-126.00K	-359.00K	-300.00K	0.00
Gross Profit Ratio	-1,414.86%	-226.60%	34.83%	-218.24%	-77.17%	-21,718.60%	-72.41%	0.00%	0.00%	0.00%
Research & Development	23.54M	12.68M	20.38M	27.91M	40.58M	28.15M	25.81M	17.02M	7.18M	2.93M
General & Administrative	7.37M	7.45M	8.45M	11.09M	8.28M	5.50M	6.00M	3.73M	2.46M	1.88M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	7.37M	7.45M	8.45M	11.09M	8.28M	5.50M	6.00M	3.73M	2.46M	1.88M
Other Expenses	-55.00K	0.00	-524.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	30.86M	20.13M	28.31M	39.00M	48.85M	33.65M	31.81M	20.76M	9.65M	4.81M
Cost & Expenses	30.86M	20.13M	28.31M	39.00M	48.85M	33.65M	31.81M	20.76M	9.65M	4.81M
Interest Income	2.07M	1.32M	257.00K	943.00K	1.37M	0.00	0.00	0.00	0.00	40.00K
Interest Expense	0.00	1.32M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	342.00K	562.00K	880.00K	946.00K	887.00K	762.00K	300.00K	359.00K	300.00K	225.00K
EBITDA	-28.96M	-15.68M	3.84M	-29.29M	-25.06M	-32.76M	-31.16M	-20.40M	-9.35M	-4.58M
EBITDA Ratio	-1,863.77%	-403.86%	9.48%	-344.69%	-109.43%	-25,394.57%	-17,909.20%	0.00%	0.00%	0.00%
Operating Income	-29.31M	-16.24M	2.08M	-30.23M	25.95M	-33.52M	-31.63M	-20.76M	-9.65M	-4.81M
Operating Income Ratio	-1,885.78%	-418.34%	6.66%	-344.69%	113.30%	-25,985.27%	-18,179.89%	0.00%	0.00%	0.00%
Total Other Income/Expenses	2.07M	1.32M	257.00K	943.00K	1.37M	1.32M	65.00K	-15.00K	-13.00K	-40.00K
Income Before Tax	-27.24M	-14.92M	3.22M	-29.29M	-24.58M	-32.20M	-31.57M	-20.77M	-9.66M	-4.85M
Income Before Tax Ratio	-1,752.77%	-384.32%	10.30%	-333.94%	-107.30%	-24,963.57%	-18,142.53%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	-1.32M	-1.14M	-1.89M	33.00K	-1.32M	-65.00K	15.00K	13.00K	0.00
Net Income	-27.24M	-13.60M	4.36M	-27.40M	-24.61M	-32.20M	-31.57M	-20.77M	-9.66M	-4.85M
Net Income Ratio	-1,752.77%	-350.30%	13.94%	-312.40%	-107.44%	-24,963.57%	-18,142.53%	0.00%	0.00%	0.00%
EPS	-1.01	-0.59	0.19	-1.21	-1.26	-1.80	-1.76	-1.77	-0.82	-1.81
EPS Diluted	-1.01	-0.59	0.18	-1.21	-1.26	-1.80	-1.76	-1.77	-0.82	-1.81
Weighted Avg Shares Out	27.09M	23.13M	23.06M	22.57M	19.53M	17.87M	17.99M	11.74M	11.74M	2.68M
Weighted Avg Shares Out (Dil)	27.09M	23.13M	23.57M	22.57M	19.53M	17.87M	17.99M	11.74M	11.74M	2.68M

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates

May 12, 2023zacks.com

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22.

Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

March 20, 2023globenewswire.com

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline, today announced that it will present at H.C....

7 Biotech Stocks That Could Be the Next Big Thing

March 15, 2023investorplace.com

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide...